Aura Biosciences (NASDAQ:AURA) Rating Lowered to Hold at Zacks Investment Research

Aura Biosciences (NASDAQ:AURAGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company’s lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. “

Shares of AURA traded up $0.53 during mid-day trading on Friday, hitting $17.01. The company’s stock had a trading volume of 56,798 shares, compared to its average volume of 36,460. Aura Biosciences has a one year low of $13.50 and a one year high of $26.16. The stock’s 50-day moving average is $18.50 and its two-hundred day moving average is $18.39.

Aura Biosciences (NASDAQ:AURAGet Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.14. Equities analysts predict that Aura Biosciences will post -2.03 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Citigroup Inc. acquired a new position in shares of Aura Biosciences in the fourth quarter valued at $31,000. New York State Common Retirement Fund acquired a new position in Aura Biosciences during the fourth quarter worth $45,000. California State Teachers Retirement System acquired a new position in Aura Biosciences during the fourth quarter worth $51,000. Wells Fargo & Company MN acquired a new position in Aura Biosciences during the fourth quarter worth $55,000. Finally, Deutsche Bank AG acquired a new position in Aura Biosciences during the fourth quarter worth $56,000. Institutional investors and hedge funds own 51.69% of the company’s stock.

About Aura Biosciences (Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

Featured Stories

Get a free copy of the Zacks research report on Aura Biosciences (AURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.